Shawn Li

Has grant

Professor

Western University
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Western Biotherapeutics Centre (WBC)

Open Date: 2023-06-12

Close Date:

Grant: Close

CL3 Pathogen Research Center: Expansion for Microbial Transmission and GMP Antimicrobial Production

Open Date: 2022-10-04

Close Date:

Grant: Close

Systematic characterization of the enzyme-substrate network in protein Lysine methylation

Open Date: 2021-04-01

Close Date: 2022-03-31

Grant: Close

Mechanism of resistance to anti-PD-1/L1 immunotherapy and strategies to overcome resistance

Open Date: 2020-11-01

Close Date: 2022-10-31

Grant: Close

Rapid Identification of immunogenic and T cell epitopes to enable serologic testing, passive immunotherapy, and epitope vaccine for COVID-19

Open Date: 2020-05-15

Close Date: 2025-05-14

Articles (9)

Year:

2026

Brain metastasis occurs in up to 40% of patients with non–small cell lung cancer (NSCLC). Considerable genomic heterogeneity exists between the primary lung tumor and respective brain metastasis; however, the identity of the genes capable of driving brain metastasis is incompletely understood. Here, we carried out an in vivo genome-wide CRISPR activation screen to identify molecular drivers of brain metastasis from an orthotopic xenograft model derived from a patient with NSCLC. We found that activating expression of the Alzheimer’s disease–associated beta-secretase 1 (BACE1) led to a substantial increase in brain metastases. Furthermore, genetic and pharmacological inhibition of BACE1 blocked NSCLC brain metastasis. Mechanistically, we identified that BACE1 acts through epidermal growth factor receptor to drive this metastatic phenotype. Together, our data highlight the power of in vivo CRISPR activation screening to unveil molecular drivers and potential therapeutic targets of NSCLC brain metastasis.

Year:

2025

Chronic myeloid leukemia (CML) resistance to BCR-ABL tyrosine kinase inhibitors (TKIs) can arise from ABL kinase domain mutations, BCR-ABL fusion gene amplification, or kinase-independent mechanisms. To investigate imatinib-resistance, we performed quantitative mass spectrometry comparing the proteome and phosphoproteome of K562 cells (a standard CML model) and ImR cells, an imatinib-resistant K562 derivative that also exhibits cross-resistance to second- and third-generation BCR-ABL TKIs. In addition to revealing global proteome and phosphoproteome changes associated with drug resistance, we identified LIN28A—a multi-functional RNA-binding protein—as a critical mediator of imatinib resistance. LIN28A was significantly overexpressed and hyperphosphorylated in ImR cells. Depleting LIN28A via shRNA restored imatinib sensitivity, while its ectopic expression in parental K562 cells induced imatinib resistance. Mechanistically, LIN28A coordinates an extensive kinase-substrate network regulating proliferation, survival, and metabolism to drive resistance. Notably, pharmacological inhibition of LIN28A-dependent kinases (PKC, AKT, SGK1, and RPS6K) suppressed ImR proliferation. Midostaurin, a clinical PKC/FLT3 inhibitor used in FLT3-ITD—positive AML, potently re-sensitized ImR cells to imatinib. Our findings suggest that targeting LIN28A and its downstream effectors, particularly PKC, could overcome resistance to imatinib and next-generation BCR-ABL inhibitors.

Year:

2025

Epithelial ovarian cancer (EOC) is a leading cause of gynecological cancer mortality, driven largely by late diagnosis and chemo-resistant disease. While autophagy plays a critical role in the survival of EOC spheroids during metastasis, the role of ULK1, a key regulator of autophagy, in EOC progression remains unclear. To investigate this, we utilized CRISPR/Cas9 technology to delete ULK1 in EOC cell lines OVCAR8 and HEYA8, and the immortalized fallopian tube epithelial cell line FT190. Immunoblotting confirmed ULK1 loss and its associated autophagy disruption in EOC spheroids, evidenced by reduced Beclin-1 phosphorylation, impaired LC3 processing, and p62 accumulation. Culture-based assays revealed that ULK1 knockout decreased EOC spheroid cell viability due to increased apoptosis and, notably, impaired matrix-bound organoid growth, offering new insights into the potential role of ULK1 in affecting EOC tumor growth and spread. These findings were further demonstrated by in vivo xenograft models, in which ULK1 loss significantly reduced tumor burden and metastatic potential. The potential for ULK1 requirement in metastatic properties was supported by diminished invasive capacity of ULK1 knockout spheroid cells in mesothelial clearance assays. To investigate the mechanisms by which ULK1 contributes EOC tumor progression and metastasis, we conducted proteomic analyses of OVCAR8 spheroids, which revealed that ULK1 loss disrupted critical signaling pathways, including MEK-MAPK, PI3K-AKT-mTOR, and apoptosis regulation. Although ULK1 knockout failed to synergize with standard-of-care chemotherapeutics, it significantly enhanced sensitivity to MEK and mTOR inhibition, revealing potential therapeutic combinations to target autophagy via ULK1 and MAPK and PI3K-AKT-mTOR pathway vulnerabilities in EOC. Overall, this study highlights ULK1 as a critical regulator of multiple steps of EOC growth and metastasis, underscoring its potential as a novel therapeutic target in advanced ovarian cancer.

Year:

2025

Tumor-associated macrophages (TAMs) are among the most abundant immune cells associated with tumors, which often exhibit immune regulatory phenotypes that promote tumor growth and confer resistance to anti-tumor immune therapies. Despite extensive efforts in developing immunotherapeutic strategies aimed at controlling the recruitment or reprogramming of TAMs, success has been limited due to strategic caveats, underscoring the need for a novel approach targeting the TAMs. PU.1, a lineage-dependent transcription factor, is highly expressed throughout the lifespan of macrophages. We have found that inhibition of PU.1 by the small molecule DB2313 suppresses melanoma tumor growth in mice through enhanced tumor recruitment of CD4+ T helper cells and cytotoxic T/NK cells mediated by TAMs. Whole transcriptome and targeted gene expression analyses revealed that DB2313 upregulates CXCL9 expression in bone marrow-derived macrophages (BMDMs) and TAMs. The anti-tumor effects of DB2313 were abolished by depleting macrophages with clodronate or inhibiting the CXCL9-CXCR3 chemokine axis using neutralizing antibodies against CXCL9 or CXCR3. Collectively, these results suggest that pharmacological inhibition of PU.1 suppresses tumor growth by promoting tumor infiltrating lymphocytes through the CXCL9-CXCR3 chemokine axis. Our study establishes a framework for developing TAM-modulating immunotherapies by targeting the transcriptional factor PU.1.

Year:

2024

Epithelial ovarian cancer (EOC) is a leading cause of gynecological cancer mortality, driven largely by late diagnosis and chemo-resistant disease. While autophagy plays a critical role in the survival of EOC spheroids during metastasis, the role of ULK1, a key regulator of autophagy, in EOC progression remains unclear. To investigate this, we utilized CRISPR/Cas9 technology to delete ULK1 in EOC cell lines OVCAR8 and HEYA8, and the immortalized fallopian tube epithelial cell line FT190. Immunoblotting confirmed ULK1 deletion, which disrupted autophagy by blocking LC3 processing, causing p62 accumulation, and decreasing Beclin-1 phosphorylation. Culture-based assays revealed that ULK1 knockout decreased EOC spheroid cell viability due to increased apoptosis, and its loss impaired organoid growth. In vivo xenograft models demonstrated that ULK1 loss significantly reduced tumor burden and metastatic potential. These in vivo findings were supported by results from mesothelial clearance assays, which showed reduced spheroid invasion by ULK1 knockout cells. Proteomic analyses of OVCAR8 spheroids revealed dysregulation due to ULK1 loss in key signaling pathways, including MAPK, mTOR-PI3K-AKT, and apoptosis regulation. Overall, this study highlights ULK1 as a critical regulator of multiple steps of EOC growth and metastasis, underscoring its potential as a novel therapeutic target in advanced ovarian cancer.

Year:

2024

Phosphorylation of proteins on tyrosine (Tyr) residues evolved in metazoan organisms as a mechanism of coordinating tissue growth 1 . Multicellular eukaryotes typically have more than 50 distinct protein Tyr kinases that catalyse the phosphorylation of thousands of Tyr residues throughout the proteome 1–3 . How a given Tyr kinase can phosphorylate a specific subset of proteins at unique Tyr sites is only partially understood 4–7 . Here we used combinatorial peptide arrays to profile the substrate sequence specificity of all human Tyr kinases. Globally, the Tyr kinases demonstrate considerable diversity in optimal patterns of residues surrounding the site of phosphorylation, revealing the functional organization of the human Tyr kinome by substrate motif preference. Using this information, Tyr kinases that are most compatible with phosphorylating any Tyr site can be identified. Analysis of mass spectrometry phosphoproteomic datasets using this compendium of kinase specificities accurately identifies specific Tyr kinases that are dysregulated in cells after stimulation with growth factors, treatment with anti-cancer drugs or expression of oncogenic variants. Furthermore, the topology of known Tyr signalling networks naturally emerged from a comparison of the sequence specificities of the Tyr kinases and the SH2 phosphotyrosine (pTyr)-binding domains. Finally we show that the intrinsic substrate specificity of Tyr kinases has remained fundamentally unchanged from worms to humans, suggesting that the fidelity between Tyr kinases and their protein substrate sequences has been maintained across hundreds of millions of years of evolution.

Year:

2024

Year:

2022

Year:

2022

Collaborators (22)

Jongmyung Kim

Assistant Professor

University of South Florida

UNITED STATES
View details

Qi Zhang

University of Western Ontario

CANADA
View details

Owen Hovey

Karolinska Institutet

SWEDEN
View details

Benjamin E. Turk

Yale University School of Medicine

UNITED STATES
View details

Olivier Elemento

Professor

Weill Cornell Medical College

UNITED STATES
View details

Sheila K. Singh

McMaster University

CANADA
View details

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

Sung Ouk Kim

Associate Professor

University of Western Ontario

CANADA
View details

Trevor Shepherd

Professor

Western University

CANADA
View details

Jason Moffat

Senior Scientist and Program Head

Hospital for Sick Children

CANADA
View details

Ariana Huebner

University College London

UNITED KINGDOM
View details

Jian‐Qiang Lu

Neuropathologist

McMaster University Faculty of Health Sciences

CANADA
View details

Mark T. Bedford

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Blessing Bassey-Archibong

Assistant Professor

Concordia University of Edmonton

CANADA
View details

Lewis Cantley

Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Kui Zhai

McMaster University

CANADA
View details

Ilka U Heinemann

University of Western Ontario

CANADA
View details

Neil Vasan

Assistant Professor, Director of Breast Cancer Translational Research, Co-Leader of Cancer Cell Biology Program

NYU Langone Health

UNITED STATES
View details

Antoine Dufour

Professor

University of Calgary

CANADA
View details

James K. C. Liu

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Shawn Chafe

Research Associate

McMaster University

CANADA
View details

Richard Wynn

Associate Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details